Evidence map›Paper›PMID 31043953›Full record

ArticleCase reports in oncology

First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.

Hiroyasu Oda, Mikiya Ishihara, Yoshihiro Miyahara, Junko Nakamura, Yuji Kozuka, Motoh Iwasa, Akira Tsunoda, Yoshiki Yamashita, Kanako Saito, Toshiro Mizuno and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Effector memory CD4Science immunology · 2022
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hiroyasu OdaDepartment of Medical Oncology, Mie University Hospital, Mie, Japan.
Mikiya IshiharaDepartment of Medical Oncology, Mie University Hospital, Mie, Japan.
Yoshihiro MiyaharaDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan.
Junko NakamuraDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan.
Yuji KozukaDepartment of Pathology, Mie University Graduate School of Medicine, Mie, Japan.
Motoh IwasaDepartment of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Mie, Japan.
Akira TsunodaDepartment of Medical Oncology, Mie University Hospital, Mie, Japan.
Yoshiki YamashitaDepartment of Medical Oncology, Mie University Hospital, Mie, Japan.
Kanako SaitoDepartment of Medical Oncology, Mie University Hospital, Mie, Japan.
Toshiro MizunoDepartment of Medical Oncology, Mie University Hospital, Mie, Japan.
Hiroshi ShikuDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan.
Naoyuki KatayamaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.
Mie University · JPMie University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCytokine release syndrome (CRS) is a potentially life-threatening systemic disease that has been observed after treatment with antibodies and adoptive T cell therapies. In this case, we observed nivolumab-induced CRS in a patient with gastric cancer. CASE PRESENTATION: A 43-year-old male with advanced gastric cancer was treated with nivolumab as a third-line chemotherapy. He had no history of allergies. Eight days after the first administration of nivolumab, fever, tachycardia, appetite loss and increases in liver and biliary enzymes were observed. Computed tomography revealed neither bile duct obstruction nor progression of liver metastases but showed that there was edema of the Gleason sheath. Histopathological analysis of the liver revealed cholestatic liver injury with CD8+ T lymphocyte and macrophage infiltration. Neither viral infection nor autoimmune disease was revealed. His symptoms were similar to those of CRS observed after T cell therapy. We diagnosed his disease as nivolumab-induced liver injury and cholangitis accompanied by CRS based on his serum cytokine levels. DISCUSSION/

conclusionTo the best of our knowledge, this is the first report of nivolumab-induced CRS in a patient with gastric cancer.

Indexed as

Cytokine release syndromeGastric cancerLiver injuryNivolumabTNF-α

Identifiers

PMID31043953
PMCPMC6477485
OpenAlexW2914899410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.